fallopian tube cancer

Showing 1 - 25 of 384

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

High Grade Serous Adenocarcinoma of Ovary, Fallopian Tube Cancer, Primary Peritoneal Carcinoma Trial (Sovilnesib)

Not yet recruiting
  • High Grade Serous Adenocarcinoma of Ovary
  • +3 more
  • (no location specified)
Oct 13, 2023

SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing

Not yet recruiting
  • Abnormal Uterine Bleeding
  • +7 more
  • Closure of the Vaginal Cuff after Total Hysterectomy
  • Frankfurt/Main, Hessen, Germany
  • +1 more
Sep 5, 2023

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Beijing (HS-20089)

Not yet recruiting
  • Ovarian Cancer
  • +3 more
  • Beijing, Beijing, China
    Lingying Wu
Aug 22, 2023

Ovarian Cancer, Ovarian Tumor, Ovarian Tumor Epithelial Trial (MIRRORS Protocol, Standard Open Cytoreductive Surgery)

Not yet recruiting
  • Ovarian Cancer
  • +5 more
  • MIRRORS Protocol
  • Standard Open Cytoreductive Surgery
  • (no location specified)
Jul 17, 2023

Cervical Cancer, Endometrial Cancer, Ovarian Cancer Trial in Seoul (Patient registry)

Recruiting
  • Cervical Cancer
  • +4 more
  • Patient registry
  • Seoul, Korea, Republic of
    Department of Obstetrics and Gynecology, University of Ulsan Col
Jun 12, 2023

Ovary Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial in Aurora (Mirvetuximab Soravtansine, Olaparib)

Not yet recruiting
  • Ovary Cancer
  • +2 more
  • Aurora, Colorado
    University of Colorado Hospital
May 30, 2023

Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer Trial (Luveltamab tazevibulin, Pegfilgrastim)

Not yet recruiting
  • Ovarian Cancer
  • +4 more
  • (no location specified)
May 12, 2023

Melanoma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma Trial in Australia (AI-061)

Not yet recruiting
  • Melanoma
  • +16 more
  • Darlinghurst, New South Wales, Australia
  • +3 more
May 12, 2023

Ovarian Cancer, Peritoneal Carcinomatosis, Fallopian Tube Cancer Trial in Shanghai (Recombinant oncolytic herpes simplex virus

Recruiting
  • Ovarian Cancer
  • +2 more
  • Recombinant oncolytic herpes simplex virus type 1 (R130)
  • Shanghai, Shanghai, China
    Shanghai Tenth People's Hospital
Mar 26, 2023

Primary Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer Trial (Huaier granule)

Not yet recruiting
  • Primary Ovarian Cancer
  • +2 more
  • Huaier granule
  • (no location specified)
Mar 29, 2023

NSCLC, Gastric Cancer, Head Neck Cancer Trial (CDX-585)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +13 more
  • (no location specified)
Mar 29, 2023

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Houston (Paclitaxel, Carboplatin, Bevacizumab)

Recruiting
  • Ovarian Cancer
  • +2 more
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Feb 13, 2023

Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer Trial in United States (PRO1184)

Recruiting
  • Ovarian Cancer
  • +8 more
  • Scottsdale, Arizona
  • +11 more
Jan 31, 2023

Cancer, Solid Tumor, Ovarian Cancer Trial in Minneapolis (FT538, Enoblituzumab)

Not yet recruiting
  • Cancer
  • +4 more
  • Minneapolis, Minnesota
    Masonic Cancer Center - University of Minnesota
Jan 24, 2023

High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Cambridge (Upifitimab rilsodotin,

Recruiting
  • High Grade Serous Ovarian Cancer
  • +2 more
  • Upifitimab rilsodotin
  • Placebo
  • Phoenix, Arizona
  • +40 more
Jan 25, 2023

Effectiveness in Ovarian Cancer

Completed
  • Ovarian Cancer
  • +5 more
  • Baseline Biopsy
  • +2 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Jan 24, 2023

Triple Negative Breast Cancer, Breast Cancer, Endometrial Cancer Trial in New York, Fairfax, Spokane (XMT-1660)

Recruiting
  • Triple Negative Breast Cancer
  • +5 more
  • Orange, California
  • +6 more
Jan 23, 2023

Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial in Worldwide (Mirvetuximab Soravtansine)

Completed
  • Epithelial Ovarian Cancer
  • +2 more
  • Mirvetuximab Soravtansine
  • Phoenix, Arizona
  • +88 more
Jan 19, 2023

Homologous Recombination Inquiry Through Ovarian Malignancy

Completed
  • Ovarian Cancer
  • +2 more
    • Niigata city, Niigata Prefecture, Japan
      Niigata University Graduate School of Medical and Dental Science
    Jan 19, 2023

    Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in New Haven, Baltimore (Ixabepilone,

    Active, not recruiting
    • Epithelial Ovarian Cancer
    • +2 more
    • New Haven, Connecticut
    • +1 more
    Jan 11, 2023

    Ovarian Cancer, Peritoneal Carcinomatosis, Fallopian Tube Cancer Trial in Newport Beach, Orlando (GL-ONC1 alone, or in

    Completed
    • Ovarian Cancer
    • +2 more
    • GL-ONC1 alone, or in combination with chemotherapy with or without bevacizumab
    • Newport Beach, California
    • +1 more
    Jan 3, 2023

    Mucinous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Seoul (Bevacizumab + modified FOLFIRINOX)

    Recruiting
    • Mucinous Ovarian Cancer
    • +2 more
    • Bevacizumab + modified FOLFIRINOX
    • Seoul, Korea, Republic of
      Yonsei University Health System, Severance Hospital
    Dec 25, 2022